{"id":913944,"date":"2025-11-26T06:33:55","date_gmt":"2025-11-26T11:33:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\/"},"modified":"2025-11-26T06:33:55","modified_gmt":"2025-11-26T11:33:55","slug":"immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\/","title":{"rendered":"Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n NEW YORK<\/span>
\n <\/span>, Nov. 26, 2025<\/span><\/span> \/PRNewswire\/ — Immunic, Inc.<\/a><\/b>\u00a0(Nasdaq: IMUX)<\/b>,\u00a0a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced\u00a0that Daniel Vitt<\/span>, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 4, 2025<\/span> at 9:35 am ET<\/span> at the 8th Annual Evercore ISI Healthcare Conference, taking place December 2-4, 2025<\/span> in Coral Gables, FL.<\/span><\/p>\n

A webcast will be available on the “Events and Presentations” section of Immunic’s website at: https:\/\/ir.imux.com\/events-and-presentations<\/a><\/u>.<\/p>\n

Dr. Vitt and Jason\u00a0Tardio, President and Chief Operating Officer of Immunic, will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Evercore ISI representative or Jessica Breu<\/span> at: jessica.breu@imux.com<\/a><\/u>.<\/p>\n

\n About Immunic, Inc.
<\/b>Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases. The company’s lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit:\u00a0www.imux.com<\/a>.<\/p>\n

\n Cautionary Statement Regarding Forward-Looking Statements
<\/b>This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management’s and employee’s participation in investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine<\/span> \u2013 Russia<\/span> conflict and the conflict in the Middle East<\/span> on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024<\/span>, filed with the SEC on March 31, 2025<\/span>, and in the company’s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov<\/a> or ir.imux.com\/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.<\/p>\n

\n Contact Information<\/b>\n <\/p>\n

\n Immunic, Inc.<\/b>
\n
\n Jessica Breu<\/span>
\n
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com<\/a><\/p>\n

\n US IR Contact<\/b>
\n
Rx Communications Group
Paula Schwartz<\/span>
+1 917 633 7790
immunic@rxir.com<\/a><\/p>\n

\n US Media Contact<\/b>
\n
KCSA Strategic Communications
Caitlin Kasunich<\/span>
+1 212 896 1241
ckasunich@kcsa.com<\/a><\/p>\n

\n

\n
\n \"Immunic,
\n <\/a>\n <\/p>\n<\/p><\/div>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december-302623149.html<\/a><\/p>\n

SOURCE Immunic, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK , Nov. 26, 2025 \/PRNewswire\/ — Immunic, Inc.\u00a0(Nasdaq: IMUX),\u00a0a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced\u00a0that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 4, 2025 at 9:35 am ET at the 8th Annual Evercore ISI Healthcare Conference, taking place December 2-4, 2025 in Coral Gables, FL. A webcast will be available on the “Events and Presentations” section of Immunic’s website at: https:\/\/ir.imux.com\/events-and-presentations. Dr. Vitt and Jason\u00a0Tardio, President and Chief Operating Officer of Immunic, will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Evercore ISI representative or Jessica Breu … <\/p>\n

Continue reading “Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-913944","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nImmunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK , Nov. 26, 2025 \/PRNewswire\/ — Immunic, Inc.\u00a0(Nasdaq: IMUX),\u00a0a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced\u00a0that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 4, 2025 at 9:35 am ET at the 8th Annual Evercore ISI Healthcare Conference, taking place December 2-4, 2025 in Coral Gables, FL. A webcast will be available on the “Events and Presentations” section of Immunic’s website at: https:\/\/ir.imux.com\/events-and-presentations. Dr. Vitt and Jason\u00a0Tardio, President and Chief Operating Officer of Immunic, will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Evercore ISI representative or Jessica Breu … Continue reading "Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-26T11:33:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December\",\"datePublished\":\"2025-11-26T11:33:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\\\/\"},\"wordCount\":806,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/871073\\\/Immunic_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\\\/\",\"name\":\"Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/871073\\\/Immunic_Logo.jpg\",\"datePublished\":\"2025-11-26T11:33:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/871073\\\/Immunic_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/871073\\\/Immunic_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\/","og_locale":"en_US","og_type":"article","og_title":"Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December - Market Newsdesk","og_description":"PR Newswire NEW YORK , Nov. 26, 2025 \/PRNewswire\/ — Immunic, Inc.\u00a0(Nasdaq: IMUX),\u00a0a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced\u00a0that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 4, 2025 at 9:35 am ET at the 8th Annual Evercore ISI Healthcare Conference, taking place December 2-4, 2025 in Coral Gables, FL. A webcast will be available on the “Events and Presentations” section of Immunic’s website at: https:\/\/ir.imux.com\/events-and-presentations. Dr. Vitt and Jason\u00a0Tardio, President and Chief Operating Officer of Immunic, will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Evercore ISI representative or Jessica Breu … Continue reading \"Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-26T11:33:55+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December","datePublished":"2025-11-26T11:33:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\/"},"wordCount":806,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\/","name":"Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg","datePublished":"2025-11-26T11:33:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/871073\/Immunic_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immunic-to-participate-in-the-8th-annual-evercore-isi-healthcare-conference-in-december\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/913944","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=913944"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/913944\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=913944"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=913944"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=913944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}